The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design
Open accessAbstract
Rationale: Optimal secondary prevention of embolic stroke of undetermined source is not established. The current standard in these patients is acetylsalicylic acid, despite high prevalence of yet undetected paroxysmal atrial fibrillation. Aim: The ATTICUS randomized trial is designed to determine whether the factor Xa inhibitor apixaban administered within 7 days after embolic stroke of undetermined source, is superior to acetylsalicylic acid for prevention of new ischemic lesions documented by brain magnetic resonance imaging within 12 months after index stroke. Design: Prospective, randomized, blinded, parallel-group, open-label, German multicenter phase III trial in approximately 500 patients with embolic stroke of undetermined source. A key inclusion criterion is the presence or the planned implantation of an insertable cardiac monitor. Patients are 1:1 randomized to apixaban or acetylsalicylic acid and treated for a 12-month period. It is an event-driven trial aiming for core-lab adjudicated primary outcome events. Study outcomes: The primary outcome is the occurrence of at least one new ischemic lesion identified by axial T2-weighted FLAIR magnetic resonance imaging and/or axial DWI magnetic resonance imaging at 12 months when compared with the baseline magnetic resonance imaging. Key secondary outcomes are the combination of recurrent ischemic strokes, hemorrhagic strokes, systemic embolism; combination of MACE including recurrent stroke, myocardial infarction, and cardiovascular death and combination of major and clinically relevant non-major bleeding defined according to ISTH, and change of cognitive function and quality of life (EQ-5D, Stroke Impact Scale). Discussion: Embolic stroke of undetermined source is caused by embolic disease and associated with a high risk of recurrent ischemic strokes and clinically silent cerebral ischemic lesions. ATTICUS will investigate the impact of atrial fibrillation detected by insertable cardiac monitor and the effects of early anticoagulation with apixaban compared with antiplatelet therapy with acetylsalicylic acid on the incidence of new ischemic lesion after embolic stroke of undetermined source.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Cryptogenic stroke and underlying atrial fibrillation
Sanna, T., Diener, H.-C., Passman, R. S., Di Lazzaro, V., Bernstein, R. A., Morillo, C. A., Rymer, M. M., Thijs, V., Rogers, T., Beckers, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313600 · Cited by 2,161
Self-citationSubclinical atrial fibrillation and the risk of stroke
Healey, J. S., Connolly, S. J., Gold, M. R., Israel, C. W., Van Gelder, I. C., Capucci, A., Lau, C. P., Fain, E., Yang, S., Bailleul, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105575 · Cited by 2,100 · cited 1×
“007).(11) There is unmet scientific need to clarify whether asymptomatic AF detected by ICM causally relates to the index stroke, because not all strokes, even in patients with documented AF are due to arrhythmia.”
BackgroundA comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke
Mohr, J. P., Thompson, J. L. P., Lazar, R. M., Levin, B., Sacco, R. L., Furie, K. L., Kistler, J. P., Albers, G. W., Pettigrew, L. C., Adams, H. P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011258 · Cited by 1,168
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
Sacco, R. L., Diener, H.-C., Yusuf, S., Cotton, D., Ôunpuu, S., Lawton, W. A., Palesch, Y., Martin, R. H., Albers, G. W., Bath, P., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805002 · Cited by 961
Debette, S., Beiser, A., DeCarli, C., Au, R., Himali, J. J., Kelly-Hayes, M., Romero, J. R., Kase, C. S., Wolf, P. A., & Seshadri, S. (2010) · Stroke · doi:10.1161/strokeaha.109.570044 · Cited by 508
Prevalence and Correlates of Silent Cerebral Infarcts in the Framingham Offspring Study
Das, R. R., Seshadri, S., Beiser, A. S., Kelly-Hayes, M., Au, R., Himali, J. J., Kase, C. S., Benjamin, E. J., Polak, J. F., O'Donnell, C. J., et al. (2008) · Stroke · doi:10.1161/strokeaha.108.516575 · Cited by 324
Validity of EQ-5D-5L in stroke
Golicki, D., Niewada, M., Buczek, J., Karlińska, A., Kobayashi, A., Janssen, M. F., & Pickard, A. S. (2015) · Quality of Life Research · doi:10.1007/s11136-014-0834-1 · Cited by 254
Cited by
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
Hart, R. G., Sharma, M., Mundl, H., Kasner, S. E., Bangdiwala, S. I., Berkowitz, S. D., Swaminathan, B., Lavados, P., Wang, Y., Wang, Y., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802686 · Cited by 1,028
Kamel, H., Longstreth, W., Tirschwell, D. L., Kronmal, R. A., Broderick, J. P., Palesch, Y. Y., Meinzer, C., Dillon, C., Ewing, I., Spilker, J. A., et al. (2019) · International Journal of Stroke · doi:10.1177/1747493018799981 · Cited by 380
Metadata
- Authors
- Geisler, T., Poli, S., Meisner, C., Schreieck, J., Zuern, C. S., Nägele, T., Brachmann, J., Jung, W., Gahn, G., Schmid, E., Bäezner, H., Keller, T., Petzold, G. C., Schrickel, J.-W., Liman, J., Wachter, R., Schön, F., Schabet, M., Lindner, A., Ludolph, A. C., Kimmig, H., Jander, S., Schlegel, U., Gawaz, M., & Ziemann, U.
- Venue
- International Journal of Stroke
- Publisher
- SAGE Publications
- Published
- 2016-11-23
- Volume
- 12
- Issue
- 9
- Pages
- 985-990
- ISSN
- 1747-4930 (ISSN-L)
- 1747-4949
- OpenAlex
- W2549334493
- Cited by
- 163
- References
- 9
- FWCI
- 14.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. https://app.cochat.ai/papers/10.1177/1747493016681019
- The paper
- Geisler, T., Poli, S., Meisner, C., Schreieck, J., Zuern, C. S., Nägele, T., Brachmann, J., Jung, W., Gahn, G., Schmid, E., Bäezner, H., Keller, T., Petzold, G. C., Schrickel, J.-W., Liman, J., Wachter, R., Schön, F., Schabet, M., Lindner, A., . . . Ziemann, U. (2017). Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. International Journal of Stroke. https://doi.org/10.1177/1747493016681019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.